Public Willingness to Participate in COVID-19 Vaccine Clinical Trials: A Study from Jordan.
Public Willingness to Participate in COVID-19 Vaccine Clinical Trials: A Study from Jordan.
复制标题
DOI：
10.2147/ppa.s284385
复制
发表时间：
2020
影响因子：
2.2
通讯作者：
Khabour OF
中科院分区：
文献类型：
--
作者：
Abu-Farha RK;Alzoubi KH;Khabour OF
研制和生产预防新冠肺炎的新型疫苗是关系人类生活的国际当务之急。为此，临床试验必须按照国际道德标准进行。目前进行的这项研究是为了检查参与新冠肺炎疫苗临床试验的意愿，并确定可能影响他们决定参加的因素。在约旦公众中进行了一项横断面调查研究。在研究期间，方便抽样的成年人(18岁或以上)被要求通过在线自我管理调查参与，该调查旨在评估参与新冠肺炎疫苗临床试验的意愿，并确定影响他们决定参与的因素。结果显示，在参与者(n=1287)中，361%的人报告愿意参加疫苗的临床试验。此外，愿意允许子女参与的比例较低(18.1%)。鼓励参与的动机是希望恢复正常生活的愿望(73.2%)，其次是希望帮助寻找治疗新冠肺炎感染的方法(68.1%)。参与的障碍是不想被病毒挑战(54.7%)、恐惧(40.7%)、缺乏时间(40.4%)和对制药公司的不信任(38.9%)。最后，研究结果显示，受教育程度越高，参与新冠肺炎疫苗临床试验的意愿越低(P=0.001)，而有过临床研究经历的患者，参与新冠肺炎疫苗临床试验的意愿越高(P<；0.001)。很大一部分约旦人对参与新冠肺炎疫苗的临床研究持积极态度。教育水平和以前参与临床研究是这种意愿的决定因素之一。此外，恐惧和缺乏时间是参与的障碍之一。
The development and production of novel vaccine to prevent COVID-19 is an international imperative to human lives. For that purpose, clinical trials have to be carried out as per international ethical standards. The current study was undertaken to examine the willingness to participate in COVID-19 vaccine clinical trials and to determine factors that might affect their decision to participate. A cross-sectional survey study was carried out among the public in Jordan. During the study period, a convenience sample of adults (aged 18 years or above) were asked to participate via an online self-administered survey that was designed to evaluate the willingness to participate in COVID-19 vaccine clinical trials and to determine factors affecting their decision to participate. Results showed that, among participants (n=1,287), 36.1% reported to be willing to participate in clinical trials of the vaccine. Additionally, a lower percentage (18.1%) were willing to allow their children to participate. Motivators that encourage participation were the desire to return to normal life (73.2%), followed by the desire to help in finding a treatment for COVID-19 infection (68.1%). Barriers towards the participation were not wanting to be challenged by the virus (54.7%), fear (40.7%), lack of time (40.4%), and mistrust in pharmaceutical companies (38.9%). Finally, results showed that higher educational level was associated with lower willingness to participate (P=0.001), whereas having a previous participation in clinical studies is associated with a significantly higher willingness to participate in COVID-19 vaccine clinical trials (P<0.001). A good portion of Jordanians are positive regarding participation in clinical studies of COVID-19 vaccine. Educational level and previous participation in clinical studies were among the determinants of such willingness. In addition, fear and lack of time were among the barriers of participation.